Benefits, risks and indications of COX-2 selective NSAIDS revisited: focus on Celecoxib

Cédric Hermans Published in the journal : May 2017 Category : Actualité thérapeutique

Summary :

Due to their anti-inflammatory and analgesic properties, induced by the inhibition of cyclooxygenase, NSAIDs are among the most widely prescribed drugs. In order to improve digestive tolerance, NSAIDs selectively targeting cyclooxygenase 2 or selective COX-2 inhibitors (COXIBS) have been developed. Despite their digestive benefits, these molecules have fallen into disfavour following documentation of an increase in cardiovascular events associated with the use of Rofecoxib. Several recent publications detailed in this article demonstrate, however, that among COXIBS, Celecoxib used in low doses has a favorable cardiovascular safety profile associated with excellent digestive tolerance, suggesting that the role of this molecule should be re-evaluated. This article reviews the advantages, modalities and precautions of Celecoxib use. Key Words NSAIDs, COXIBS, cardiovascular risk, Gastrointestinal haemorrhage, Celecoxib